CJC-1295 vs sermorelin: amwpeptides comparison
The useful comparison starts with what each experiment measured, then asks whether the outcome travels.
Structure and duration
Sermorelin reproduces the active GHRH(1-29) fragment. CJC-1295 adds stabilizing substitutions; its DAC form also binds albumin, producing prolonged exposure. These design differences sit within the shared GHRH receptor pharmacology.
For CJC-1295 vs sermorelin, the familiar short-versus-long description is incomplete. With sermorelin, GH remained elevated for about three hours despite rapid peptide clearance. With CJC-1295, estimated peptide half-life was 5.8-8.1 days, while IGF-1 remained elevated for 9-11 days after a single study administration. Peptide half-life and hormone-response duration are different quantities. I object to comparisons that silently exchange them.
Participants and outcomes
| Compound | People studied | Measured finding |
|---|---|---|
| Sermorelin | Prepubertal children with GH deficiency | Accelerated first-year height velocity |
| Sermorelin | Healthy older men | Higher 24-hour GH and IGF-1 over 14 days |
| CJC-1295 | Healthy adults | Sustained GH and IGF-1 elevation |
| CJC-1295 | 11 healthy young men | Exploratory serum protein changes |
| Tesamorelin | Adults with HIV and abdominal fat accumulation | Reduced visceral and liver fat versus placebo |
An overall winner would be a strange prize for such mismatched contests. The childhood height result, the adult hormone response and the HIV fat result answer different questions. None of the studies in this list directly establishes which of CJC-1295 or sermorelin delivers better long-term adult wellness outcomes.
Albumin-binding variants
The multi-day CJC-1295 findings concern the long-acting DAC form. Modified GRF (1-29), often described as CJC-1295 no-DAC, lacks the albumin-binding attachment. Its shorter action makes the name confusion consequential.
The study of GH pulses during CJC-1295 stimulation is sometimes recruited into the argument that longer action is automatically more physiological or safer. It found preserved pulse frequency and magnitude in healthy men, alongside elevated basal GH. For me, preserved pulsatility answers a narrowly endocrine question. A clinical safety advantage over sermorelin would need direct comparison and longer follow-up.
Approval and safety differences
Sermorelin has a former pediatric FDA approval and a current Category 1 compounding context under FDA's interim 503A policy. CJC-1295 has never been approved for human use and was not recommended for the 503A compounding bulks list in the 2024 PCAC review. Tesamorelin's 2010 FDA approval concerns HIV-associated lipodystrophy. For these compounds, a compounded medicine has no FDA approval.
All three are prohibited in sport under WADA S2. Glucose handling, fluid retention and elevated IGF-1 remain relevant safety concerns, with the gaps differing by compound. The skeptical editorial on secretagogues for aging challenges the assumption that restoring hormone numbers establishes a useful adult intervention.
Where tesamorelin helps the comparison
Tesamorelin shows what happens when a related molecule reaches trials with an anatomical outcome. The randomized HIV study measured visceral fat and liver fat; the longer program followed persistence and withdrawal. Those observations give the comparison substance.
They also expose its limits. Transferring the result to sermorelin or CJC-1295 changes the molecule; transferring it to general fat loss changes the population and indication. A direct trial using the same clinical outcome and the same kind of participants could establish a comparative adult clinical benefit. Until then, the sermorelin record and CJC-1295 record earn different, carefully bounded conclusions.